S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:NKTR

Nektar Therapeutics Competitors

$16.48
-0.21 (-1.26 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$16.35
Now: $16.48
$16.75
50-Day Range
$15.77
MA: $17.03
$18.13
52-Week Range
$13.63
Now: $16.48
$28.60
Volume643,552 shs
Average Volume1.37 million shs
Market Capitalization$2.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88

Competitors

Nektar Therapeutics (NASDAQ:NKTR) Vs. JNJ, PFE, MRK, ABBV, BMY, and LLY

Should you be buying NKTR stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Nektar Therapeutics, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Eli Lilly and (LLY).

Nektar Therapeutics (NASDAQ:NKTR) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-264.38%-28.23%-20.37%
Johnson & Johnson21.01%34.64%13.40%

Valuation and Earnings

This table compares Nektar Therapeutics and Johnson & Johnson's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54
Johnson & Johnson$82.06 billion4.61$15.12 billion$8.6816.55

Johnson & Johnson has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 67.4% of Johnson & Johnson shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Johnson & Johnson, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics15702.46
Johnson & Johnson031002.77

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Johnson & Johnson has a consensus price target of $166.0769, suggesting a potential upside of 15.59%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-264.38%-28.23%-20.37%
Pfizer28.80%25.11%9.52%

Valuation and Earnings

This table compares Nektar Therapeutics and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54
Pfizer$51.75 billion3.92$16.27 billion$2.9512.38

Pfizer has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 69.1% of Pfizer shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Pfizer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics15702.46
Pfizer09502.36

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Pfizer has a consensus price target of $40.00, suggesting a potential upside of 9.50%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Pfizer.

Nektar Therapeutics (NASDAQ:NKTR) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Nektar Therapeutics and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-264.38%-28.23%-20.37%
Merck & Co., Inc.24.33%55.13%16.98%

Valuation and Earnings

This table compares Nektar Therapeutics and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54
Merck & Co., Inc.$46.84 billion4.32$9.84 billion$5.1915.43

Merck & Co., Inc. has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Merck & Co., Inc. shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics15702.46
Merck & Co., Inc.021302.87

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. Merck & Co., Inc. has a consensus price target of $95.3333, suggesting a potential upside of 19.08%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Merck & Co., Inc..

Summary

Merck & Co., Inc. beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Insider & Institutional Ownership

96.4% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 64.2% of AbbVie shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nektar Therapeutics and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics15702.46
AbbVie141602.71

Nektar Therapeutics currently has a consensus price target of $31.8182, suggesting a potential upside of 93.07%. AbbVie has a consensus price target of $111.00, suggesting a potential upside of 6.53%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than AbbVie.

Profitability

This table compares Nektar Therapeutics and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-264.38%-28.23%-20.37%
AbbVie18.16%439.24%13.22%

Volatility and Risk

Nektar Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nektar Therapeutics and AbbVie's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54
AbbVie$33.27 billion5.53$7.88 billion$8.9411.66

AbbVie has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional & Insider Ownership

64.8% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 96.4% of Nektar Therapeutics shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Bristol-Myers Squibb and Nektar Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb041202.75
Nektar Therapeutics15702.46

Bristol-Myers Squibb currently has a consensus target price of $74.20, suggesting a potential upside of 18.08%. Nektar Therapeutics has a consensus target price of $31.8182, suggesting a potential upside of 93.07%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Bristol-Myers Squibb.

Profitability

This table compares Bristol-Myers Squibb and Nektar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Nektar Therapeutics-264.38%-28.23%-20.37%

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bristol-Myers Squibb and Nektar Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.44$3.44 billion$4.6913.40
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54

Bristol-Myers Squibb has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional & Insider Ownership

76.4% of Eli Lilly and shares are owned by institutional investors. Comparatively, 96.4% of Nektar Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Eli Lilly and and Nektar Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and05912.73
Nektar Therapeutics15702.46

Eli Lilly and currently has a consensus target price of $168.9286, suggesting a potential upside of 16.70%. Nektar Therapeutics has a consensus target price of $31.8182, suggesting a potential upside of 93.07%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Eli Lilly and.

Profitability

This table compares Eli Lilly and and Nektar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Nektar Therapeutics-264.38%-28.23%-20.37%

Volatility and Risk

Eli Lilly and has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Eli Lilly and and Nektar Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion6.20$8.32 billion$6.0423.97
Nektar Therapeutics$114.62 million25.79$-440,670,000.00($2.52)-6.54

Eli Lilly and has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats Nektar Therapeutics on 10 of the 15 factors compared between the two stocks.


Nektar Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.5$143.68-0.1%$378.24 billion$82.06 billion22.59Ex-Dividend
Pfizer logo
PFE
Pfizer
2.6$36.53-0.2%$203.05 billion$51.75 billion14.50Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$80.06-0.1%$202.55 billion$46.84 billion17.71
AbbVie logo
ABBV
AbbVie
2.7$104.20-0.2%$183.96 billion$33.27 billion22.03
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$62.84-0.6%$142.19 billion$26.15 billion-571.22Insider Selling
Eli Lilly and logo
LLY
Eli Lilly and
2.4$144.75-0.1%$138.47 billion$22.32 billion23.65
Zoetis logo
ZTS
Zoetis
1.8$160.19-0.5%$76.13 billion$6.26 billion47.53Insider Selling
Royalty Pharma logo
RPRX
Royalty Pharma
1.8$40.97-3.4%$15.90 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.2$68.90-0.2%$15.21 billion$1.30 billion18.83Analyst Downgrade
Mylan logo
MYL
Mylan
1.8$15.86-0.0%$8.59 billion$11.50 billion29.92High Trading Volume
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$141.83-0.7%$7.90 billion$2.16 billion44.74
Perrigo logo
PRGO
Perrigo
2.4$47.93-1.0%$6.54 billion$4.84 billion27.55
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$63.36-1.5%$2.75 billion$421.03 million-253.44
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$22.83-0.2%$2.65 billion$306.49 million25.65Analyst Revision
Endo International logo
ENDP
Endo International
1.1$5.30-3.4%$1.22 billion$2.91 billion-7.79
Zogenix logo
ZGNX
Zogenix
1.7$21.08-0.6%$1.17 billion$3.65 million-2.22
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.6$21.33-0.6%$1.12 billion$392.76 million9.65
Omeros logo
OMER
Omeros
1.4$11.71-2.9%$721.95 million$111.81 million-5.71Analyst Report
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.72-0.3%$376.13 million$111.39 million26.57
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$6.09-0.2%$277.95 million$16.54 million-2.03
Lannett logo
LCI
Lannett
2.1$6.28-1.8%$261.41 million$545.74 million-8.72
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$5.70-3.2%$188.23 million$15.96 million-3.45High Trading Volume
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.0$2.91-2.1%$43.76 million$47.53 million-13.23
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.